

Estimate change 

TP change 

Rating change 

Bloomberg	SBILIFE IN
Equity Shares (m)	1000
M.Cap.(INRb)/(USDb)	1117.9 / 13.7
52-Week Range (INR)	1340 / 1035
1, 6, 12 Rel. Per (%)	-5/-12/-1
12M Avg Val (INR M)	1420

Financials & Valuations (INR b)

Y/E MARCH	FY23	FY24E	FY25E
Net Premiums	665.8	795.2	961.8
Surplus / Deficit	28.6	24.0	26.8
Sh. PAT	17.2	20.0	23.1
NBP gr- unwt'd (%)	16.2	19.0	21.0
NBP gr- APE (%)	18.4	18.6	21.4
Premium gr (%)	14.6	19.1	20.9
VNB margin (%)	30.1	29.5	30.0
RoEV (%)	16.2	22.6	21.6
Total AUMs (INRt)	3.1	3.6	4.3
VNB	50.7	58.7	72.6
EV per share	460	564	686

Valuations

P/EV (x)	2.4	2.0	1.6
P/EVOP (x)	12.3	11.1	9.2

*VNB, VNB margins based on ETR

Shareholding pattern (%)

As On	Mar-23	Dec-22	Mar-22
Promoter	55.5	55.5	55.5
DII	15.1	14.9	12.5
FII	25.1	25.1	24.2
Others	4.3	4.5	7.9

FII Includes depository receipts

CMP: INR1,117 TP: INR1,500 (+34%)

BUY

Premium growth inline; VNB margin expands to 31.6%

Persistency improves across cohorts

- SBILIFE reported an inline 4QFY23. APE grew 10% YoY (inline), while VNB grew 23% YoY, as margins expanded 380bp QoQ to 31.6%, driven by higher growth in Non-PAR. PAT grew 16% YoY to INR7.8b (10% beat).
- Among segments, Annuity saw a healthy growth of 78% YoY, while Non-Par savings grew 65% YoY in 4QFY23. Growth in the Protection business was modest at 12% YoY, while the ULIP business saw a decline.
- We slightly lower our VNB margin estimates and expect VNB margins to remain at ~30% in FY25. We expect SBILIFE to deliver a 20% CAGR in APE over FY23-25, thus enabling a 20% VNB CAGR. RoEV is expected to hover around ~22-23%. We reiterate our BUY rating on the stock.

Robust trends in Non-PAR/Annuity continues

- SBILIFE reported 14% YoY growth in gross premium (in line), led by 10%/42% growth in renewal/single premium. Shareholders' PAT grew 16% YoY to INR7.8b (10% beat). For FY23, PAT grew 14% YoY to INR17.2b.
- Total APE grew 10% YoY (inline), within which, Non-Par savings and Annuity grew 65% and 78% YoY, respectively. The Protection business grew 12% YoY, led by 39% growth in group protection and a sequential pick-up in individual protection growth. Par products grew 36% YoY, while ULIP saw a decline of 9% YoY (down 33% QoQ).
- The share of ULIP declined to 52% (vs 65% in 3QFY23), while Non-par savings stood at 23% v/s 15% in 4QFY22. SBILIFE does not have any internal cap on the share of this segment and will continue to underwrite as long as it can effectively hedge the interest rate risk. Protection mix stood at ~12% v/s 8% in 3QFY23.
- Absolute VNB grew 23% YoY to INR14.4b (up 37% YoY in FY23). VNB margins expanded 380bp QoQ to 31.6%, driven by higher growth in Non-Par and Annuity. For FY23, VNB margin stood at 30.1%.
- On the distribution front, the banca channel increased 7% YoY, while the agency channel grew 15% YoY on APE basis.
- Persistency improved across cohorts, with 13M/61M persistency increasing by 100bp/200bp YoY at 85.5%/55.6%.

Highlights from the management commentary

- Growth outlook – As demand remains robust, growth momentum is expected to sustain at a rate of 20-25% in FY24.
- EOM regulation changes will lead to designing products creatively for customers as well as distributors
- Margins can increase only up to a certain point and it is expected that margins would remain in the range of 29-30%. The focus will be on growing VNB and EV.

Valuation and view

SBILIFE reported a steady quarter, with an inline APE and VNB margins expanding to 31.6%, driven by higher growth in Non-Par and Annuity. ULIPs saw a decline while the Protection business saw a healthy QoQ pick-up. All the distribution channels continued to see a rise in productivity, which resulted in a better cost ratio; SBI Life continues to maintain its cost leadership. Persistency too saw an improvement across all cohorts. We estimate a 20% CAGR in APE over FY32-25 and estimate VNB margin to remain at ~30% in FY25, thus enabling a 20% VNB CAGR. RoEV is expected to stay around ~22%. We reiterate our **BUY rating with a TP of INR1,500 (2.4x Sep'24E EV)**.

Quarterly performance**(INR b)**

Policy holder's A/c (INR b)	FY22				FY23				FY22	FY23	FY23E 4QE	V/s est.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
First year premium	14.0	36.1	40.7	38.5	25.7	34.8	50.6	40.9	129.4	152.0	43.1	(5.1)
Growth (%)	29%	56%	24%	5%	83%	-4%	24%	6%	25%	17%	12%	
Renewal premium	50.3	77.8	96.5	108.4	57.6	91.2	109.1	119.4	333.0	377.3	123.1	(3.1)
Growth (%)	10%	9%	14%	15%	14%	17%	13%	10%	12%	13%	14%	
Single premium	19.4	33.3	44.3	28.1	30.2	40.2	33.7	39.9	125.2	143.9	37.1	7.4
Growth (%)	-2%	-8%	105%	11%	56%	20%	-24%	42%	22%	15%	32%	
Gross premium	83.8	147.2	181.6	175.1	113.5	166.2	193.3	200.1	587.6	673.2	203.3	(1.6)
Growth (%)	10%	12%	31%	12%	35%	13%	6%	14%	17%	15%	16%	
PAT	2.2	2.5	3.6	6.7	2.6	3.8	3.0	7.8	15.1	17.2	7.1	9.7
Growth (%)	-43%	-18%	56%	26%	18%	53%	-16%	16%	3%	14%	5%	
Key metrics (INRb)												
New Business APE	16.2	39.7	45.7	41.3	29.0	39.3	54.3	45.5	141.9	168.1	45.7	(0.4)
Growth (%)	27.6	46.5	30.6	4.0	79.0	-1.0	18.8	10.2	24.9	18.4	10.6	
VNB	3.8	10.0	11.5	11.7	8.8	12.4	15.1	14.4	37.0	50.7	13.5	6.3
Growth (%)	46.2	85.2	51.3	6.4	131.6	24.0	31.3	23.1	39.1	37.0	15.8	
AUM	2,316	2,442	2,569	2,674	2,624	2,826	3,000	3,073	2,674	3,073	3,123	(1.6)
Growth (%)	32.1	31.0	22.6	21.1	13.3	15.7	16.8	14.9	21.1	14.9	16.8	
Key Ratios (%)												
VNB margins (%)	23.7	25.2	25.2	28.3	30.4	31.6	27.8	31.6	25.9	30.1	29.7	(198)
Solvency ratio (%)	215.0	212.0	209.0	205.0	221.0	219.0	225.0	215.0	204.8	215.0	221.1	613

Quarterly snapshot

Policyholder A/C (INR b)	FY21				FY22				FY23				Change (%)	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	YoY	QoQ
Net premium income	75.9	128.6	137.7	155.6	83.1	146.6	180.3	174.3	110.4	164.8	191.7	199.0	14	4
First year prem	10.9	23.2	32.8	36.6	14.0	36.1	40.7	38.5	25.7	34.8	50.6	40.9	6	-19
Renewal prem	45.8	71.5	84.4	94.6	50.3	77.8	96.5	108.4	57.6	91.2	109.1	119.4	10	9
Single premium	19.7	36.2	21.6	25.3	19.4	33.3	44.3	28.1	30.2	40.2	33.7	39.9	42	18
Investment Income	85.8	55.9	127.8	45.1	74.1	107.3	24.2	30.0	-64.1	110.4	74.4	11.9	-60	-84
Total income	161.8	184.6	265.5	209.0	157.4	254.0	204.6	214.3	46.4	275.3	266.3	228.1	6	-14
Commission paid	2.3	4.1	5.2	5.9	2.6	5.3	6.1	6.8	5.1	7.1	8.5	8.7	29	3
Operating expenses	5.5	6.0	6.5	6.6	6.1	7.5	7.9	9.0	7.7	8.5	9.1	10.0	11	10
Total comm. & Opex	7.7	10.1	11.6	12.5	8.8	12.8	14.0	15.8	12.7	15.7	17.6	18.7	19	6
Benefits paid	28.5	64.3	46.4	76.6	47.9	127.0	64.7	73.7	51.7	76.4	83.6	91.2	24	9
Change in act. Liab	116.9	105.5	202.4	114.5	97.8	109.8	121.2	108.9	-22.7	177.3	159.4	96.0	-12	-40
Total Expenses	153.2	179.9	260.5	203.6	154.4	249.6	199.9	198.4	41.7	269.4	260.5	206.0	4	-21
PBT	8.5	3.1	3.6	3.9	1.5	2.9	2.6	13.1	3.1	3.9	3.3	19.7	50	492
Surplus/(Deficit)	6.1	3.9	3.0	5.1	1.1	2.6	2.4	12.8	2.7	3.4	3.0	19.4	52	554
Shareholder's A/C														
Trf frm policyholder	2.8	1.1	0.7	12.2	-0.4	1.3	1.7	14.7	1.0	1.9	1.1	23.0	57	1,924
Investment income	0.9	1.9	1.7	2.3	2.8	2.4	2.2	2.4	1.8	2.0	2.0	2.1	-11	5
Total income	3.8	3.1	2.4	14.5	2.4	3.8	3.9	17.1	2.8	3.9	3.2	25.2	47	694
PBT	3.9	3.0	2.3	6.2	2.3	2.5	3.8	6.9	2.7	3.9	3.1	7.9	14	155
PAT	3.9	3.0	2.3	5.3	2.2	2.5	3.6	6.7	2.6	3.8	3.0	7.8	16	155
APE Data														
Individual Savings	9.4	20.6	30.4	34.2	12.5	33.4	38.3	34.5	23.5	31.8	47.5	37.1	8	-22
Par	1.1	2.4	3.0	3.2	1.2	2.1	2.0	2.2	1.7	2.4	2.4	3.0	36	25
Non Par	2.2	2.0	3.3	3.2	1.1	4.2	5.5	6.3	8.2	9.3	9.6	10.4	65	8
ULIP	6.1	16.2	24.1	27.8	10.2	27.1	30.8	26.0	13.6	20.1	35.5	23.7	-9	-33
Group Savings	1.2	1.9	0.8	1	0.9	1.5	2.1	1	1.6	1.6	0.9	1.5	50	67
Annuity	0.5	1.1	0.6	0.8	0.7	0.7	1.2	0.9	0.7	1.3	1.4	1.6	78	14
Total Protection	1.6	3.4	3.3	3.7	2.2	4.1	4.2	4.9	3.2	4.5	4.6	5.5	12	20
Retail Protection	0.7	1.9	2.2	2.5	1.3	2.3	2.5	3.1	2.0	2.2	2.6	3.0	-3	15
Group Protection	0.9	1.5	1.1	1.2	0.9	1.8	1.7	1.8	1.2	2.3	2.0	2.5	39	25
Total APE	12.7	27	35.1	39.7	16.3	39.7	45.7	41.4	29.0	39.3	54.3	45.5	10	-16
APE (% of total)														
Individual Savings	74.0	76.3	86.6	86.1	76.7	84.1	83.8	83.3	81.0	80.9	87.5	81.5	-179	-594
Par	8.7	8.9	8.5	8.1	7.4	5.3	4.4	5.3	5.9	6.1	4.4	6.6	128	217
Non Par	17.3	7.4	9.4	8.1	6.7	10.6	12.0	15.2	28.3	23.7	17.7	22.9	764	518
ULIP	48.0	60.0	68.7	70.0	62.6	68.3	67.4	62.8	46.9	51.1	65.4	52.1	-1071	-1329
Group Savings	9.4	7.0	2.3	2.5	5.5	3.8	4.6	2.4	5.5	4.1	1.7	3.3	88	164
Annuity	3.9	4.1	1.7	2.0	4.3	1.8	2.6	2.2	2.4	3.3	2.6	3.5	134	94
Total Protection	12.6	12.6	9.4	9.3	13.5	10.3	9.2	11.8	11.0	11.5	8.5	12.1	25	362
Retail Protection	5.5	7.0	6.3	6.3	8.0	5.8	5.5	7.5	6.9	5.6	4.8	6.6	-89	181
Group Protection	7.1	5.6	3.1	3.0	5.5	4.5	3.7	4.3	4.1	5.9	3.7	5.5	115	181
Distribution mix (%)														
Banca	55.5	63.7	68.3	60.7	56.8	63.6	66.1	61.7	62.5	63.5	69.9	59.7	-201	-1019
Agency	26.6	22.6	24.6	30.7	29.0	26.6	22.8	27.6	26.5	24.5	23.6	28.7	106	505
Others	18.0	13.7	7.1	8.6	14.2	9.8	11.2	10.7	11.0	12.0	6.5	11.6	94	514
Key Ratios (%)														
Operating ratios														
Commission	2.9	3.2	3.7	3.7	3.1	3.6	3.4	3.9	4.5	4.3	4.4	4.4	48	-2
Opex	7.1	4.6	4.7	4.2	7.3	5.1	4.3	5.1	6.7	5.1	4.7	5.0	-13	28
Total Cost	10.1	7.7	8.4	8.0	10.5	8.9	7.7	9.0	11.2	9.4	9.1	9.4	35	25
Solvency ratio	239.0	245.0	234.0	215.0	215.0	212.0	209.0	205.0	221.0	219.0	225.0	215.0	1,000	-1,000

Policyholder A/C (INR b)	FY21				FY22				FY23				Change (%)	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	YoY	QoQ
Operating ratios														
VNB margins	20.1	20.3	21.9	27.7	23.7	25.2	25.2	28.3	30.4	31.6	27.8	31.6	339	384
RoE	17.3	15.0	13.0	15.2	8.5	8.8	10.3	13.7	0.0	0.0	10.4	14.0	30	360
Persistency ratios														
13th month	82.6	83.2	83.4	85.4	85.9	84.7	83.9	85.2	85.6	85.2	84.6	85.5	34	97
25th month	76.3	76.2	75.9	75.8	75.3	76.1	76.4	78.1	78.7	77.5	76.3	75.6	-251	-71
37th month	68.8	69.9	70.8	72.1	72.0	72.1	71.9	72.2	72.2	72.9	73.2	74.5	236	131
49th month	60.9	62.3	63.8	65.6	66.3	67.5	68.3	69.9	70.3	70.3	70.1	70.3	41	17
61st month	50.0	50.0	52.5	50.9	49.3	48.8	48.7	49.5	50.3	52.5	53.6	55.6	612	201
Key Metrics (INRb)														
VNB	2.6	5.4	7.6	11.0	3.8	10.0	11.5	11.7	8.8	12.4	15.1	14.4	23	-5
EV	NA	312.7	NA	364.0	NA	384.9	NA	396.3	NA	424.1	NA	460.4	NA	NA
AUM	1754	1864	2095	2209	2316	2442	2569	2674	2624	2826	3000	3073	15	2
Equity Mix (%)	24.0	24.0	27.0	27.0	28.0	30.0	29.0	29.0	27.0	29.0	29.0	29.0	0	0

Note: a) Persistency ratios are on a cumulative basis for six, nine, and 12 months



Highlights from the management commentary

Overall business

- ~2.2m new policies were sold in FY23 (up 14%) and the company has a leadership position on an NOP basis. Sum assured grew 13% YoY v/s 12% YoY for the private industry.
- **Growth outlook** – As demand remains robust, growth momentum is expected to sustain at a rate of 20-25% in FY24. EOM regulation changes will lead to designing products creatively for customers as well as distributors
- **Commission payouts** – The company will review commission payouts to all distribution partners with the objective to grow each channels. NOP growth has been healthy for SBI Life, and much higher than the competition. Distributors that add value to the company will be eligible for higher payouts.
- **No deduction regime** – The seasonality of insurance business is declining, indicating a reduction in usage of 80c benefits for insurance purchases. Also, the range of products that qualify for 80c benefits has expanded over time. Hence, even in a no deduction regime, demand for insurance is expected to remain strong.

Products

- **Protection** – Retail protection growth weakened in 4Q due to the prevalent focus on taxation, resulting in a shift toward savings products. SBI Life will continue to maintain its focus on Protection. Credit Life was INR20b in FY23 v/s INR17b in FY22 (INR6.2b in 4QFY23 vs INR5.7b in 4QFY22)
- **ULIP business** – SBI Life has a wide choice of products for customers. For FY23, it has been flattish, as the year has been influenced by higher demand for long-term guaranteed return products. Management expects some growth in the ULIP business for FY24. ULIP mix has changed from 60:40 debt: equity in the past to 48:52. Equity story for ULIPs should sustain in the near future.
- Product mix will be influenced by the prevailing demand environment. The rise in Non-Par products was due to the introduction of a new product a year ago. ULIP will be based on the return, wherein SBI Life has delivered strong returns.

- There are no foreseeable difficulties in hedging the Non-PAR business and the majority of the business is in the premium paying term of 7-10 years.

VNB and EV


- Product mix drove VNB margins and the company maintains a healthy growth in VNB
- Margins can increase only up to a certain point and it is expected that margins would remain in the range of 29-30%. The primary emphasis of the company will be on expanding VNB and EV.
- SBI Life has not changed equity market return assumptions.
- The unwinding rate is dependent on the composition of portfolio and the shape of the yield curve. The portfolio has shifted toward Non-Par business, which has longer-term tenures and the yield curve has risen.
- EV has become more sensitive to interest rates because of long-term Non-Par products, which need higher reserving, leading to excess assets. Hedging also has played a role in the same. Excess net worth has no liabilities, and causes more volatility.
- Positive operating variance is a mix of expenses, persistency, and reinsurance.

Distribution

- Banca – Non-SBI partners are growing at a healthy pace and the momentum is likely to sustain. The company will look to add more partners going ahead.
- SBI, Agency, and other banks are the key channels for achieving growth.
- In FY23, the company added 62k agents, taking the total count to 208k. The agency channel is highly productive and one of the best among private players. Since the penetration of insurance among SBI customers is currently low, there is significant potential for growth opportunity remains large.


Key exhibits

Exhibit 1: Persistency ratios across cohorts



Source: MOFSL, Company

Exhibit 2: Share of ULIP moderated to 52% of total APE




Source: MOFSL, Company

Valuation and view

- With an Individual-rated premium market share of ~22% in FY23 among private players, SBILIFE is the market leader. APE growth was healthy at 10% YoY in 4QFY23 (up 18% in FY23) and we expect a 20% CAGR in APE over FY23-25.
- In 4QFY23, the share of Non-PAR increased, driven by an increased demand due to budgetary changes; while ULIP posted a weak trend. Protection saw a healthy recovery, with the mix increasing on a sequential basis. VNB margin thus improved to 31.6%.
- **Reiterate Buy, with a TP of INR1,500:** SBILIFE reported a steady quarter, with an inline APE and VNB margins expanding to 31.6%, driven by higher growth in Non-Par and Annuity. ULIPs saw a decline, while the Protection business saw a healthy QoQ pick-up. All distribution channels continued to see a rise in productivity, resulting in a better cost ratio; SBI Life continues to maintain its cost leadership. Persistency too saw an improvement across all cohorts. We estimate a 20% CAGR in APE over FY32-25 and estimate VNB margin to remain at ~30% in FY25, thus enabling a 20% VNB CAGR. RoEV is expected to stay at around ~22%. **We reiterate our Buy rating with a TP of INR1,500 (2.4x Sep'24E EV).**


Story in charts

Exhibit 3: Net premium up 14% YoY




Source: MOFSL, Company

Exhibit 4: Renewal premium grew 10% YoY




Source: MOFSL, Company

Exhibit 5: Total expense ratio increased slightly to 9.4%




Source: MOFSL, Company

Exhibit 6: Solvency ratio remains healthy at 215%




Source: MOFSL, Company

Exhibit 7: VNB margin expands ~380bp to 31.6%



Source: MOFSL, Company; Margins based on Effective tax rate

Exhibit 8: Share of distribution mix across channels



Source: MOFSL, Company; Distribution mix based on APE

Financials and valuations

Technical account (INR b)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Gross Premiums	253.5	329.9	406.3	502.5	587.6	673.2	802.0	969.8
Reinsurance Ceded	(1.9)	(1.0)	(3.1)	(4.9)	(3.3)	(7.3)	(6.7)	(7.9)
Net Premiums	251.7	328.9	403.2	497.7	584.3	665.8	795.2	961.8
Income from Investments	84.6	112.1	30.0	314.6	235.7	132.6	220.4	255.4
Other Income	1.4	1.6	5.2	8.6	10.3	17.6	16.8	20.1
Total income (A)	337.7	442.6	438.4	820.8	830.3	816.0	1,032.4	1,237.4
Commission	11.2	13.5	16.2	17.7	21.6	29.4	30.2	36.3
Operating expenses	17.2	21.2	24.1	24.1	29.7	35.4	45.2	54.5
Total commission and opex	28.4	34.7	40.3	41.9	51.3	64.7	75.4	90.8
Benefits Paid (Net)	117.1	152.9	162.5	215.8	313.4	302.9	290.4	352.7
Chg in reserves	176.0	235.9	206.0	539.3	437.6	410.0	630.4	752.9
Prov for doubtful debts	3.5	5.5	6.8	4.7	7.8	8.3	10.1	12.5
Total expenses (B)	325.1	429.0	415.7	801.8	810.2	785.9	1,006.2	1,208.9
(A) - (B)	12.6	13.6	22.8	19.1	20.1	30.0	26.2	28.5
Prov for Tax	2.4	2.7	3.8	1.0	1.3	1.5	2.2	1.7
Surplus / Deficit (calculated)	10.2	10.9	19.0	18.1	18.8	28.6	24.0	26.8

Shareholder's a/c (INR b)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Transfer from technical a/c	8.3	10.0	14.6	16.8	17.3	27.1	20.4	23.6
Income From Investments	4.6	5.2	4.8	6.9	9.9	7.9	8.7	10.5
Total Income	12.9	15.2	19.5	23.7	27.2	35.0	29.1	34.2
Other expenses	0.6	0.6	1.0	0.6	2.9	0.4	0.5	0.7
Contribution to technical a/c	0.8	1.0	4.8	8.2	9.8	17.1	8.4	10.1
Total Expenses	1.1	1.4	5.3	8.3	11.6	17.4	8.9	10.8
PBT	11.8	13.7	14.1	15.4	15.6	17.6	20.2	23.4
Prov for Tax	0.3	0.5	(0.1)	0.9	0.5	0.4	0.2	0.3
PAT	11.5	13.3	14.2	14.6	15.1	17.2	20.0	23.1
<i>Growth</i>	20.5%	15.3%	7.2%	2.4%	3.4%	14.3%	16.2%	15.6%

Premium (INR b) & growth (%)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
New business prem - unwtd	109.7	137.9	165.9	206.2	254.6	295.9	352.1	426.0
New business prem - wrp	84.2	95.3	105.1	113.7	141.9	168.1	199.4	242.0
Renewal premium	143.9	192.0	240.4	296.3	333.0	377.3	449.9	543.7
Total premium - unwtd	253.5	329.9	406.3	502.5	587.6	673.2	802.0	969.8
New bus. growth - unwtd	8.1%	25.8%	20.3%	24.3%	23.4%	16.2%	19.0%	21.0%
New business growth - wrp	27.6%	13.2%	10.2%	8.2%	24.9%	18.4%	18.6%	21.4%
Renewal premium growth	32.3%	33.4%	25.2%	23.2%	12.4%	13.3%	19.2%	20.9%
Total prem growth - unwtd	20.6%	30.1%	23.2%	23.7%	16.9%	14.6%	19.1%	20.9%

Premium mix (%)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
New business - unwtd								
- Individual mix	76.7%	69.9%	67.8%	60.6%	64.8%	70.7%	70.0%	70.0%
- Group mix	23.3%	30.1%	32.2%	39.4%	35.2%	29.3%	30.0%	30.0%
New business mix - WRP								
- Participating	24.0%	18.4%	10.9%	8.4%	5.3%	9.5%	9.4%	9.0%
- Non-participating	9.0%	10.3%	18.6%	26.6%	28.9%	44.7%	43.7%	43.8%
- ULIPs	67.0%	71.3%	70.5%	65.0%	65.8%	46.0%	46.9%	47.2%
Total premium mix - unwtd								
- Participating	24.8%	21.8%	18.3%	15.1%	12.9%	15.9%	15.5%	15.3%
- Non-participating	19.5%	20.8%	23.8%	28.2%	30.3%	35.0%	33.7%	32.8%
- ULIPs	55.7%	57.4%	57.9%	56.6%	56.8%	49.1%	50.9%	51.9%

Individual prem sourcing mix (%)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Individual agents	31.2%	29.6%	28.8%	27.7%	26.6%	27.7%	28.4%	28.1%
Corporate agents-Banks	67.4%	68.9%	67.5%	65.4%	64.9%	65.0%	63.4%	63.0%
Direct business	0.8%	0.7%	2.0%	4.1%	5.3%	5.3%	6.0%	6.5%
Others	0.5%	0.7%	1.8%	2.8%	3.1%	2.0%	2.2%	2.4%

Financials and valuations

Balance sheet (INR b)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Sources of Fund								
Share Capital	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0
Reserves And Surplus	53.7	64.6	78.8	90.9	104.2	119.2	136.4	156.2
Shareholders' Fund	65.3	75.8	87.4	104.0	116.2	130.2	147.2	166.9
Policy Liabilities	555.6	649.5	761.2	924.1	1,097.6	1,301.3	1,602.8	1,935.6
Prov. for Linked Liab.	495.6	605.9	763.0	965.5	1,174.9	1,407.2	1,551.5	1,808.5
Funds For Future App.	-	2.8	7.1	8.4	9.9	11.4	13.5	15.9
Current liabilities & prov.	35.5	37.4	30.2	42.4	51.3	51.0	52.9	54.9
Total	1,217.1	1,467.3	1,655.8	2,268.3	2,733.4	3,146.9	3,674.6	4,368.1
Application of Funds								
Shareholders' inv	50.1	57.2	68.3	86.0	100.8	112.1	132.3	156.1
Policyholders' inv	544.9	644.7	734.2	939.4	1,121.3	1,298.7	1,647.4	1,988.1
Assets to cover linked liab.	549.4	691.3	785.7	1,162.2	1,426.3	1,632.6	1,772.6	2,079.1
Loans	1.7	1.7	3.6	3.6	3.6	3.9	4.5	5.1
Fixed Assets	5.8	6.0	5.8	5.7	5.3	5.2	5.6	6.1
Current assets	65.2	66.4	58.2	71.5	76.2	94.4	112.3	133.6
Total	1,217.1	1,467.3	1,655.8	2,268.3	2,733.4	3,146.9	3,674.6	4,368.1
Operating ratios (%)								
Investment yield	7.8%	8.4%	1.9%	15.0%	9.3%	4.4%	6.2%	6.1%
Commissions / GWP	4.4%	4.1%	4.0%	3.5%	3.7%	4.4%	3.8%	3.7%
- first year premiums	8.7%	8.3%	8.4%	8.4%	8.3%	11.9%	10.2%	10.2%
- renewal premiums	2.7%	2.7%	2.7%	2.6%	2.6%	2.5%	2.6%	2.6%
- single premiums	0.8%	1.5%	1.4%	1.1%	1.2%	1.4%	1.8%	1.8%
Operating expenses / GWP	6.8%	6.4%	5.9%	4.8%	5.1%	5.3%	5.6%	5.6%
Total expense ratio	11.2%	10.5%	9.9%	8.3%	8.7%	9.6%	9.4%	9.4%
Claims / NWP	46.4%	46.3%	40.1%	43.2%	53.5%	45.5%	36.3%	36.5%
Solvency ratio	206%	213%	195%	215%	205%	215%	212%	204%
Persistency ratios (%)								
13th Month	83.0%	85.1%	86.1%	85.4%	85.2%	85.5%	85.8%	86.0%
25th Month	75.2%	76.7%	78.5%	75.8%	78.1%	75.6%	74.0%	73.1%
37th Month	70.0%	71.4%	71.6%	72.1%	72.2%	74.5%	75.7%	76.3%
49th Month	63.9%	66.4%	67.3%	65.6%	69.9%	70.3%	70.5%	70.6%
61st Month	58.4%	57.2%	59.9%	50.9%	49.5%	55.6%	59.3%	61.5%
Profitability ratios (%)								
VNB margin (%)	18.4%	19.8%	20.7%	23.2%	25.9%	30.1%	29.5%	30.0%
RoE (%)	19.0%	18.8%	17.4%	15.2%	13.7%	14.0%	14.4%	14.7%
RoC (%)	19.4%	19.2%	17.4%	15.3%	14.0%	14.1%	14.5%	14.8%
Operating ROEV (%)	18.0%	17.3%	20.5%	19.1%	20.6%	22.9%	21.9%	21.5%
RoEV (%)	15.3%	17.5%	17.4%	27.0%	18.7%	16.2%	22.6%	21.6%
Valuation ratios								
Total AUMs	1,163	1,410	1,604	2,209	2,674	3,073	3,613	4,296
- of which equity AUMs (%)	23%	23%	21%	27%	29%	29%	31%	31%
Dividend %	20%	20%	0%	25%	20%	25%	28%	33%
Dividend payout ratio (%)	21%	18%	0%	17%	13%	15%	14%	14%
EPS, Rs	11.5	13.3	14.2	14.6	15.1	17.2	20.0	23.1
VNB	15.7	19.2	22.2	26.6	37.0	50.7	58.7	72.6
- VNB growth (%)	36.1%	22.3%	15.6%	19.8%	39.1%	37.0%	16%	24%
EV per share	201.7	237.3	276.4	364.0	396.3	460.4	564.5	686.1
VIF as % of EV	61%	62%	63%	63%	68%	70%	72%	74%
P/VIF	9.6	8.1	6.7	5.3	4.1	3.5	2.7	2.2
P/AUM (%)	96%	79%	70%	51%	42%	36%	31%	26%
P/EV (x)	5.5	4.7	4.0	3.1	2.8	2.4	2.0	1.6
P/EPs (x)	97.1	84.2	78.5	76.7	74.2	64.9	55.9	48.4
P/EVOP (x)	37.6	33.8	24.3	22.3	16.2	12.3	11.1	9.2
P/VNB (x)	71.1	58.2	50.3	42.0	30.2	22.0	19.0	15.4

*VNB, VNB margin, and EV is based on ETR

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisers Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI:

ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.